CoChat
Sign Up
Cited by 513Inflammatory Bowel DiseaseProbiotics and Fermented FoodsGut microbiota and health

The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis

Sood, Ajit, Midha, Vandana, Makharia, Govind K., Ahuja, Vineet, Singal, Dinesh, Goswami, Pooja, Tandon, Rakesh K.·2009·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2009.07.016
Open this paper in CoChat — free account

Abstract

Background & aims Probiotics can maintain ulcerative colitis (UC) in remission effectively, but little is known of their ability to induce remission. We conducted a multicenter, randomized, double-blind, placebo-controlled trial of a high-potency probiotic, VSL#3, for the treatment of mild-to-moderately active UC.Methods Adult patients with mild-to-moderate UC were assigned randomly to groups that were given 3.6 x 10(12) CFU VSL#3 (n = 77) or placebo (n = 70), twice daily for 12 weeks. The primary end point was a 50% decrease in the Ulcerative Colitis Disease Activity Index (UCDAI) at 6 weeks. The secondary end points included remission by 12 weeks and reduction in total individual UCDAI parameters from baseline at 12 weeks. Intention-to-treat analysis was performed.Results At week 6, the percentage of patients with an improvement in UCDAI score that was greater than 50% was significantly higher in the group given VSL#3 (25; 32.5%) than the group given placebo (7; 10%) (P = .001). At week 12, there were 33 patients given VSL#3 (42.9%) who achieved remission, compared with 11 patients given placebo (15.7%) (P < .001). Furthermore, significantly more patients given VSL#3 (40; 51.9%) achieved a decrease in their UCDAI that was greater than 3 points, compared with those given placebo (13; 18.6%) (P < .001). The VSL#3 group had significantly greater decreases in UCDAI scores and individual symptoms at weeks 6 and 12, compared with the placebo group.Conclusions VSL#3 is safe and effective in achieving clinical responses and remissions in patients with mild-to-moderately active UC.

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2009.07.016

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The probiotic mixture VSL#3 reduces ulcerative colitis symptoms in adults and induces remission in children.

    “In IBD, the probiotic mixture VSL#3, which contains bifidobacteria of different species, was able to reduce the UC symptoms in adults (144, 145) as well as the remission of the disease in children (84).”

    From Bifidobacteria and Their Health-Promoting Effects (2017) · cites this paper as [144]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K.
Affiliations
  • Dayanand Medical College & Hospital (IN)
  • All India Institute of Medical Sciences (IN)
  • Pushpawati Singhania Research Institute (IN)
Corresponding author
Tandon, Rakesh K.
ORCID
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2009-11
Volume
7
Issue
11
Pages
1202-1209.e1
ISSN
1542-3565 (ISSN-L)
DOI
10.1016/j.cgh.2009.07.016
OpenAlex
W2150366828
Cited by
513
References
35
Citations by year
2026: 16 · 2025: 22 · 2024: 30 · 2023: 26 · 2022: 28 · 2021: 27 · 2020: 36 · 2019: 33 · 2018: 37 · 2017: 43 · 2016: 27 · 2015: 28 · 2014: 49 · 2013: 22 · 2012: 39
FWCI
17.06
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
VSL#3, probiotics, ulcerative colitis, remission induction, inflammatory bowel disease treatment
MeSH terms
Adult, Colitis, Ulcerative, Double-Blind Method, Female, Humans, Immunologic Factors, Male, Middle Aged, Placebos, Severity of Illness Index, Probiotics, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review